Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H17ClN2O |
Molecular Weight | 324.804 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC2=C(C=C1)N(CC3CC3)C(=O)CN=C2C4=CC=CC=C4
InChI
InChIKey=MWQCHHACWWAQLJ-UHFFFAOYSA-N
InChI=1S/C19H17ClN2O/c20-15-8-9-17-16(10-15)19(14-4-2-1-3-5-14)21-11-18(23)22(17)12-13-6-7-13/h1-5,8-10,13H,6-7,11-12H2
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/1959497Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/6106488
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1959497
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/6106488
Prazepam is a benzodiazepine derivative and is indicated to treat symptoms of anxiety. Benzodiazepines are used to treat severe incapacitating symptoms or symptoms leading to an extreme suffering for the patient. Prazepam is believed to stimulate GABA receptors in the ascending reticular activating system. Since GABA is inhibitory, receptor stimulation increases inhibition and blocks both cortical and limbic arousal following stimulation of the brain stem reticular formation. Prazepam is a prodrug for N-desmethyl-diazepam, which is responsible for the therapeutic effects of prazepam. Prazepam was discontinued in USA.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=6114911 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PRAZEPAM Approved UseUnknown Launch Date1987 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/387419/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
36 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/387419/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.31 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/387419/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
20 mg 4 times / day multiple, oral Highest studied dose Dose: 20 mg, 4 times / day Route: oral Route: multiple Dose: 20 mg, 4 times / day Sources: |
unhealthy, 44 years (range: 29 - 65 years) n = 23 Health Status: unhealthy Condition: alcoholics Age Group: 44 years (range: 29 - 65 years) Sex: M Population Size: 23 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Anti-spasticity agents for multiple sclerosis. | 2001 |
|
Determination of midazolam and 1'-hydroxymidazolam by liquid chromatography-mass spectrometry in plasma of patients undergoing methadone maintenance treatment. | 2003 Jan 5 |
|
Colchicine poisoning: case report of two suicides. | 2004 Jul 16 |
|
Polyuria after olanzapine overdose. | 2004 Jun |
|
Development and validation of a liquid chromatographic/electrospray ionization mass spectrometric method for the quantitation of prazepam and its main metabolites in human plasma. | 2005 Apr |
|
Benzodiazepines prescription in Dakar: a study about prescribing habits and knowledge in general practitioners, neurologists and psychiatrists. | 2006 Jun |
|
Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine. | 2009 Apr 28 |
|
Drugs associated with more suicidal ideations are also associated with more suicide attempts. | 2009 Oct 2 |
|
Eight self-administered 24-hour dietary recalls using the Internet are feasible in African Americans and Whites: the energetics study. | 2010 Jun |
Patents
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
N05BA11
Created by
admin on Sat Dec 16 05:08:27 GMT 2023 , Edited by admin on Sat Dec 16 05:08:27 GMT 2023
|
||
|
NCI_THESAURUS |
C1012
Created by
admin on Sat Dec 16 05:08:27 GMT 2023 , Edited by admin on Sat Dec 16 05:08:27 GMT 2023
|
||
|
WHO-VATC |
QN05BA11
Created by
admin on Sat Dec 16 05:08:27 GMT 2023 , Edited by admin on Sat Dec 16 05:08:27 GMT 2023
|
||
|
DEA NO. |
2764
Created by
admin on Sat Dec 16 05:08:27 GMT 2023 , Edited by admin on Sat Dec 16 05:08:27 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID4021181
Created by
admin on Sat Dec 16 05:08:27 GMT 2023 , Edited by admin on Sat Dec 16 05:08:27 GMT 2023
|
PRIMARY | |||
|
1727
Created by
admin on Sat Dec 16 05:08:27 GMT 2023 , Edited by admin on Sat Dec 16 05:08:27 GMT 2023
|
PRIMARY | |||
|
8627
Created by
admin on Sat Dec 16 05:08:27 GMT 2023 , Edited by admin on Sat Dec 16 05:08:27 GMT 2023
|
PRIMARY | RxNorm | ||
|
D011222
Created by
admin on Sat Dec 16 05:08:27 GMT 2023 , Edited by admin on Sat Dec 16 05:08:27 GMT 2023
|
PRIMARY | |||
|
4890
Created by
admin on Sat Dec 16 05:08:27 GMT 2023 , Edited by admin on Sat Dec 16 05:08:27 GMT 2023
|
PRIMARY | |||
|
CHEMBL969
Created by
admin on Sat Dec 16 05:08:27 GMT 2023 , Edited by admin on Sat Dec 16 05:08:27 GMT 2023
|
PRIMARY | |||
|
220-975-8
Created by
admin on Sat Dec 16 05:08:27 GMT 2023 , Edited by admin on Sat Dec 16 05:08:27 GMT 2023
|
PRIMARY | |||
|
PRAZEPAM
Created by
admin on Sat Dec 16 05:08:27 GMT 2023 , Edited by admin on Sat Dec 16 05:08:27 GMT 2023
|
PRIMARY | |||
|
2240
Created by
admin on Sat Dec 16 05:08:27 GMT 2023 , Edited by admin on Sat Dec 16 05:08:27 GMT 2023
|
PRIMARY | |||
|
m9106
Created by
admin on Sat Dec 16 05:08:27 GMT 2023 , Edited by admin on Sat Dec 16 05:08:27 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB01588
Created by
admin on Sat Dec 16 05:08:27 GMT 2023 , Edited by admin on Sat Dec 16 05:08:27 GMT 2023
|
PRIMARY | |||
|
Q30VCC064M
Created by
admin on Sat Dec 16 05:08:27 GMT 2023 , Edited by admin on Sat Dec 16 05:08:27 GMT 2023
|
PRIMARY | |||
|
2955-38-6
Created by
admin on Sat Dec 16 05:08:27 GMT 2023 , Edited by admin on Sat Dec 16 05:08:27 GMT 2023
|
PRIMARY | |||
|
SUB10006MIG
Created by
admin on Sat Dec 16 05:08:27 GMT 2023 , Edited by admin on Sat Dec 16 05:08:27 GMT 2023
|
PRIMARY | |||
|
100000092249
Created by
admin on Sat Dec 16 05:08:27 GMT 2023 , Edited by admin on Sat Dec 16 05:08:27 GMT 2023
|
PRIMARY | |||
|
1554501
Created by
admin on Sat Dec 16 05:08:27 GMT 2023 , Edited by admin on Sat Dec 16 05:08:27 GMT 2023
|
PRIMARY | |||
|
277179
Created by
admin on Sat Dec 16 05:08:27 GMT 2023 , Edited by admin on Sat Dec 16 05:08:27 GMT 2023
|
PRIMARY | |||
|
7275
Created by
admin on Sat Dec 16 05:08:27 GMT 2023 , Edited by admin on Sat Dec 16 05:08:27 GMT 2023
|
PRIMARY | |||
|
C66458
Created by
admin on Sat Dec 16 05:08:27 GMT 2023 , Edited by admin on Sat Dec 16 05:08:27 GMT 2023
|
PRIMARY |
ACTIVE MOIETY